Market Overview:
The global T-cell therapy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, technological advancements in T-cell therapy, and rising demand for personalized medicine. The global T-cell therapy market is segmented on the basis of type into CAR T cell therapy, TCR Therapy, and others (TIL Therapy). The CAR T cell therapy segment is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. This growth can be attributed to the increasing number of clinical trials being conducted for CAR-T cells and their potential benefits over other therapies. The Clinics & Ambulatory Centers segment is expected to account for the largest share in terms of revenue in 2018 followed by Hospitals and Cancer Research Institutes segments. .However,.
Product Definition:
T-Cell therapy is a treatment that uses the patient's own T cells to fight cancer. The T cells are removed from the patient's blood, treated in a lab to make them more effective against cancer, and then injected back into the patient.
CAR T Cell Therapy:
A CAR T cell is a type of white blood cell (WCB) that is derived from the patient's own immune system and which can recognize and attack cancer cells without harming the WCB's normal tissue-specific targets. The therapy works by removing or destroying the cancerous cells with the help of special enzymes. These engineered WCBs are then reintroduced into the patient's body, where they patrol their specific target area for tumor cells.
TCR Therapy:
TCR therapy is a new treatment approach that involves using the patient's own immune cells to fight cancer. These are known as T-cells, which are part of the body's immune system. TCR therapy has shown great results in clinical trials and is expected to become an important tool for treating patients with advanced melanoma, lymphoma, and leukemia.
The market for TCR therapy was valued at USD 469 million in 2018.
Application Insights:
The others segment held the largest share of more than 60.0% in 2017 owing to its growing adoption for the treatment of chronic diseases, such as diabetes and rheumatoid arthritis. T-cell therapy is increasingly used for treating these diseases due to its ability to recognize and attack cancer cells, which have developed resistance against other forms of treatment.
The clinics & ambulatory centers segment is expected register a significant CAGR during the forecast period owing to increasing government funding for research on advanced therapies that target specific proteins expressed by tumor cells only. For instance, nivolumab was FDA approved in January 2015 under the brand name Opdivo for patients with unresectable or metastatic non-small cell lung cancer (NSCLC).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased funding for research and development activities, and high incidence of cancer among people in this region. The U.S holds a major share in this regional market due to its well-established healthcare sector along with growing adoption of novel treatment techniques by clinicians & researchers as well as patients.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing number of clinical trials being conducted in Asian countries for advanced therapies such as T-cell therapy compared to other regions. Moreover, governments are continuously investing funds for R&D purposes which is boosting industry growth across this region during the forecast period from 2018 To 2030 (ref).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the T-cell therapy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for T-cell therapies over the forecast period.
- Rising awareness about T-cell therapies: There is a rising awareness about T-cell therapies among patients and healthcare professionals owing to its benefits over traditional treatments such as chemotherapy and radiation therapy. This is expected to boost adoption rates of these therapies and drive market growth during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
T-Cell Therapy Market Research Report
By Type
CAR T Cell Therapy, TCR Therapy, TIL Therapy
By Application
Hospitals, Clinics & Ambulatory Centers, Cancer Research Institutes, Others
By Companies
Gilead Sciences, Inc., Sorrento Therapeutics, Fate Therapeutics Inc., Novartis International AG, AbbVie Inc., Adaptimmune Therapeutics PLC, Bluebird Bio, TCR2 Therapeutics, Inc., Pfizer Inc., DiaCarta, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global T-Cell Therapy Market Report Segments:
The global T-Cell Therapy market is segmented on the basis of:
Types
CAR T Cell Therapy, TCR Therapy, TIL Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics & Ambulatory Centers, Cancer Research Institutes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences, Inc.
- Sorrento Therapeutics
- Fate Therapeutics Inc.
- Novartis International AG
- AbbVie Inc.
- Adaptimmune Therapeutics PLC
- Bluebird Bio
- TCR2 Therapeutics, Inc.
- Pfizer Inc.
- DiaCarta, Inc.
Highlights of The T-Cell Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CAR T Cell Therapy
- TCR Therapy
- TIL Therapy
- By Application:
- Hospitals
- Clinics & Ambulatory Centers
- Cancer Research Institutes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the T-Cell Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
T-Cell therapy is a treatment for cancer that uses T cells to attack and destroy the cancer.
Some of the major companies in the t-cell therapy market are Gilead Sciences, Inc., Sorrento Therapeutics, Fate Therapeutics Inc., Novartis International AG, AbbVie Inc., Adaptimmune Therapeutics PLC, Bluebird Bio, TCR2 Therapeutics, Inc., Pfizer Inc., DiaCarta, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 T-Cell Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 T-Cell Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 T-Cell Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the T-Cell Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global T-Cell Therapy Market Size & Forecast, 2018-2028
4.5.1 T-Cell Therapy Market Size and Y-o-Y Growth
4.5.2 T-Cell Therapy Market Absolute $ Opportunity
Chapter 5 Global T-Cell Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 T-Cell Therapy Market Size Forecast by Type
5.2.1 CAR T Cell Therapy
5.2.2 TCR Therapy
5.2.3 TIL Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global T-Cell Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 T-Cell Therapy Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics & Ambulatory Centers
6.2.3 Cancer Research Institutes
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global T-Cell Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 T-Cell Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America T-Cell Therapy Analysis and Forecast
9.1 Introduction
9.2 North America T-Cell Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America T-Cell Therapy Market Size Forecast by Type
9.6.1 CAR T Cell Therapy
9.6.2 TCR Therapy
9.6.3 TIL Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America T-Cell Therapy Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics & Ambulatory Centers
9.10.3 Cancer Research Institutes
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe T-Cell Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe T-Cell Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe T-Cell Therapy Market Size Forecast by Type
10.6.1 CAR T Cell Therapy
10.6.2 TCR Therapy
10.6.3 TIL Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe T-Cell Therapy Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics & Ambulatory Centers
10.10.3 Cancer Research Institutes
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific T-Cell Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific T-Cell Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific T-Cell Therapy Market Size Forecast by Type
11.6.1 CAR T Cell Therapy
11.6.2 TCR Therapy
11.6.3 TIL Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific T-Cell Therapy Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics & Ambulatory Centers
11.10.3 Cancer Research Institutes
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America T-Cell Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America T-Cell Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America T-Cell Therapy Market Size Forecast by Type
12.6.1 CAR T Cell Therapy
12.6.2 TCR Therapy
12.6.3 TIL Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America T-Cell Therapy Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics & Ambulatory Centers
12.10.3 Cancer Research Institutes
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) T-Cell Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) T-Cell Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) T-Cell Therapy Market Size Forecast by Type
13.6.1 CAR T Cell Therapy
13.6.2 TCR Therapy
13.6.3 TIL Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) T-Cell Therapy Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics & Ambulatory Centers
13.10.3 Cancer Research Institutes
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 T-Cell Therapy Market: Competitive Dashboard
14.2 Global T-Cell Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences, Inc.
14.3.2 Sorrento Therapeutics
14.3.3 Fate Therapeutics Inc.
14.3.4 Novartis International AG
14.3.5 AbbVie Inc.
14.3.6 Adaptimmune Therapeutics PLC
14.3.7 Bluebird Bio
14.3.8 TCR2 Therapeutics, Inc.
14.3.9 Pfizer Inc.
14.3.10 DiaCarta, Inc.
